Zacks Investment Research upgraded shares of Stealth BioTherapeutics (NASDAQ:MITO) from a hold rating to a buy rating in a report published on Wednesday morning, Zacks.com reports. They currently have $13.00 target price on the stock.
According to Zacks, “Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company’s product pipeline includes Elamipretide, SBT-20 and SBT-272 which are in clinical stage. Stealth BioTherapeutics Corp is based in Newton, Massachusetts. “
Separately, HC Wainwright reissued a buy rating and issued a $30.00 price objective on shares of Stealth BioTherapeutics in a research report on Friday, July 12th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Stealth BioTherapeutics presently has an average rating of Buy and a consensus price target of $24.33.
Shares of MITO opened at $10.00 on Wednesday. The company has a 50-day moving average price of $12.07. Stealth BioTherapeutics has a one year low of $10.00 and a one year high of $20.99.
Stealth BioTherapeutics (NASDAQ:MITO) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. On average, sell-side analysts expect that Stealth BioTherapeutics will post -0.14 earnings per share for the current year.
An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC bought a new position in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned 0.18% of Stealth BioTherapeutics as of its most recent filing with the SEC. Institutional investors own 0.73% of the company’s stock.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.